Clinical Trial Update: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic and pharmacogenomic study of ribociclib in race-based cohorts for breast cancer was terminated; results were posted on 2024-11-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Georgetown University | Conditions: Breast Cancer | Phase 4 | Status: TERMINATED | Results posted: 2024-11-26